Comparative Survival in Patients With Postresection Recurrent Versus Newly Diagnosed Non-Small-Cell Lung Cancer Treated With Radiotherapy

Xu Wei Cai, Lu Ying Xu, Li Wang, James A. Hayman, Andrew C. Chang, Allan Pickens, Kemp B. Cease, Mark B. Orringer, Feng Ming Kong

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: To compare the survival of postresection recurrent vs. newly diagnosed non-small-cell lung cancer (NSCLC) patients treated with radiotherapy or chemoradiotherapy. Methods and Materials: The study population consisted of 661 consecutive patients with NSCLC registered in the radiation oncology databases at two medical centers in the United States between 1992 and 2004. Of the 661 patients, 54 had postresection recurrent NSCLC and 607 had newly diagnosed NSCLC. Kaplan-Meier and Cox regression models were used for the survival analyses. Results: The distribution of relevant clinical factors between these two groups was similar. The median survival time and 5-year overall survival rates were 19.8 months (95% confidence interval [CI], 13.9-25.7) and 14.8% (95% confidence interval, 5.4-24.2%) vs. 12.2 months (95% CI, 10.8-13.6) and 11.0% (95% CI, 8.5-13.5%) for recurrent vs. newly diagnosed patients, respectively (p = .037). For Stage I-III patients, no significant difference was observed in the 5-year overall survival (p = .297) or progression-free survival (p = .935) between recurrent and newly diagnosed patients. For the 46 patients with Stage I-III recurrent disease, multivariate analysis showed that chemotherapy was a significant prognostic factor for 5-year progression-free survival (hazard ratio, 0.45; 95% CI, 0.224-0.914; p = .027). Conclusion: Our institutional data have shown that patients with postresection recurrent NSCLC achieved survival comparable to that of newly diagnosed NSCLC patients when they were both treated with radiotherapy or chemoradiotherapy. These findings suggest that patients with postresection recurrent NSCLC should be treated as aggressively as those with newly diagnosed disease.

Original languageEnglish (US)
Pages (from-to)1100-1105
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume76
Issue number4
DOIs
StatePublished - Mar 15 2010

Fingerprint

Non-Small Cell Lung Carcinoma
lungs
radiation therapy
Radiotherapy
cancer
Survival
confidence
Confidence Intervals
intervals
Chemoradiotherapy
progressions
Disease-Free Survival
Hospital Distribution Systems
Radiation Oncology
chemotherapy
Survival Analysis
Proportional Hazards Models
hazards
regression analysis
Multivariate Analysis

Keywords

  • Non-small-cell lung cancer
  • chemotherapy
  • postresection recurrence
  • radiotherapy
  • survival

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Comparative Survival in Patients With Postresection Recurrent Versus Newly Diagnosed Non-Small-Cell Lung Cancer Treated With Radiotherapy. / Cai, Xu Wei; Xu, Lu Ying; Wang, Li; Hayman, James A.; Chang, Andrew C.; Pickens, Allan; Cease, Kemp B.; Orringer, Mark B.; Kong, Feng Ming.

In: International Journal of Radiation Oncology Biology Physics, Vol. 76, No. 4, 15.03.2010, p. 1100-1105.

Research output: Contribution to journalArticle

Cai, Xu Wei ; Xu, Lu Ying ; Wang, Li ; Hayman, James A. ; Chang, Andrew C. ; Pickens, Allan ; Cease, Kemp B. ; Orringer, Mark B. ; Kong, Feng Ming. / Comparative Survival in Patients With Postresection Recurrent Versus Newly Diagnosed Non-Small-Cell Lung Cancer Treated With Radiotherapy. In: International Journal of Radiation Oncology Biology Physics. 2010 ; Vol. 76, No. 4. pp. 1100-1105.
@article{bcec9d30e23d49cba6c993633827fa83,
title = "Comparative Survival in Patients With Postresection Recurrent Versus Newly Diagnosed Non-Small-Cell Lung Cancer Treated With Radiotherapy",
abstract = "Purpose: To compare the survival of postresection recurrent vs. newly diagnosed non-small-cell lung cancer (NSCLC) patients treated with radiotherapy or chemoradiotherapy. Methods and Materials: The study population consisted of 661 consecutive patients with NSCLC registered in the radiation oncology databases at two medical centers in the United States between 1992 and 2004. Of the 661 patients, 54 had postresection recurrent NSCLC and 607 had newly diagnosed NSCLC. Kaplan-Meier and Cox regression models were used for the survival analyses. Results: The distribution of relevant clinical factors between these two groups was similar. The median survival time and 5-year overall survival rates were 19.8 months (95{\%} confidence interval [CI], 13.9-25.7) and 14.8{\%} (95{\%} confidence interval, 5.4-24.2{\%}) vs. 12.2 months (95{\%} CI, 10.8-13.6) and 11.0{\%} (95{\%} CI, 8.5-13.5{\%}) for recurrent vs. newly diagnosed patients, respectively (p = .037). For Stage I-III patients, no significant difference was observed in the 5-year overall survival (p = .297) or progression-free survival (p = .935) between recurrent and newly diagnosed patients. For the 46 patients with Stage I-III recurrent disease, multivariate analysis showed that chemotherapy was a significant prognostic factor for 5-year progression-free survival (hazard ratio, 0.45; 95{\%} CI, 0.224-0.914; p = .027). Conclusion: Our institutional data have shown that patients with postresection recurrent NSCLC achieved survival comparable to that of newly diagnosed NSCLC patients when they were both treated with radiotherapy or chemoradiotherapy. These findings suggest that patients with postresection recurrent NSCLC should be treated as aggressively as those with newly diagnosed disease.",
keywords = "Non-small-cell lung cancer, chemotherapy, postresection recurrence, radiotherapy, survival",
author = "Cai, {Xu Wei} and Xu, {Lu Ying} and Li Wang and Hayman, {James A.} and Chang, {Andrew C.} and Allan Pickens and Cease, {Kemp B.} and Orringer, {Mark B.} and Kong, {Feng Ming}",
year = "2010",
month = "3",
day = "15",
doi = "10.1016/j.ijrobp.2009.03.017",
language = "English (US)",
volume = "76",
pages = "1100--1105",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Comparative Survival in Patients With Postresection Recurrent Versus Newly Diagnosed Non-Small-Cell Lung Cancer Treated With Radiotherapy

AU - Cai, Xu Wei

AU - Xu, Lu Ying

AU - Wang, Li

AU - Hayman, James A.

AU - Chang, Andrew C.

AU - Pickens, Allan

AU - Cease, Kemp B.

AU - Orringer, Mark B.

AU - Kong, Feng Ming

PY - 2010/3/15

Y1 - 2010/3/15

N2 - Purpose: To compare the survival of postresection recurrent vs. newly diagnosed non-small-cell lung cancer (NSCLC) patients treated with radiotherapy or chemoradiotherapy. Methods and Materials: The study population consisted of 661 consecutive patients with NSCLC registered in the radiation oncology databases at two medical centers in the United States between 1992 and 2004. Of the 661 patients, 54 had postresection recurrent NSCLC and 607 had newly diagnosed NSCLC. Kaplan-Meier and Cox regression models were used for the survival analyses. Results: The distribution of relevant clinical factors between these two groups was similar. The median survival time and 5-year overall survival rates were 19.8 months (95% confidence interval [CI], 13.9-25.7) and 14.8% (95% confidence interval, 5.4-24.2%) vs. 12.2 months (95% CI, 10.8-13.6) and 11.0% (95% CI, 8.5-13.5%) for recurrent vs. newly diagnosed patients, respectively (p = .037). For Stage I-III patients, no significant difference was observed in the 5-year overall survival (p = .297) or progression-free survival (p = .935) between recurrent and newly diagnosed patients. For the 46 patients with Stage I-III recurrent disease, multivariate analysis showed that chemotherapy was a significant prognostic factor for 5-year progression-free survival (hazard ratio, 0.45; 95% CI, 0.224-0.914; p = .027). Conclusion: Our institutional data have shown that patients with postresection recurrent NSCLC achieved survival comparable to that of newly diagnosed NSCLC patients when they were both treated with radiotherapy or chemoradiotherapy. These findings suggest that patients with postresection recurrent NSCLC should be treated as aggressively as those with newly diagnosed disease.

AB - Purpose: To compare the survival of postresection recurrent vs. newly diagnosed non-small-cell lung cancer (NSCLC) patients treated with radiotherapy or chemoradiotherapy. Methods and Materials: The study population consisted of 661 consecutive patients with NSCLC registered in the radiation oncology databases at two medical centers in the United States between 1992 and 2004. Of the 661 patients, 54 had postresection recurrent NSCLC and 607 had newly diagnosed NSCLC. Kaplan-Meier and Cox regression models were used for the survival analyses. Results: The distribution of relevant clinical factors between these two groups was similar. The median survival time and 5-year overall survival rates were 19.8 months (95% confidence interval [CI], 13.9-25.7) and 14.8% (95% confidence interval, 5.4-24.2%) vs. 12.2 months (95% CI, 10.8-13.6) and 11.0% (95% CI, 8.5-13.5%) for recurrent vs. newly diagnosed patients, respectively (p = .037). For Stage I-III patients, no significant difference was observed in the 5-year overall survival (p = .297) or progression-free survival (p = .935) between recurrent and newly diagnosed patients. For the 46 patients with Stage I-III recurrent disease, multivariate analysis showed that chemotherapy was a significant prognostic factor for 5-year progression-free survival (hazard ratio, 0.45; 95% CI, 0.224-0.914; p = .027). Conclusion: Our institutional data have shown that patients with postresection recurrent NSCLC achieved survival comparable to that of newly diagnosed NSCLC patients when they were both treated with radiotherapy or chemoradiotherapy. These findings suggest that patients with postresection recurrent NSCLC should be treated as aggressively as those with newly diagnosed disease.

KW - Non-small-cell lung cancer

KW - chemotherapy

KW - postresection recurrence

KW - radiotherapy

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=77449111926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449111926&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.03.017

DO - 10.1016/j.ijrobp.2009.03.017

M3 - Article

C2 - 19540063

AN - SCOPUS:77449111926

VL - 76

SP - 1100

EP - 1105

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -